Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2144)
11/10/2023
Indication
As monotherapy for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with national guidance
Formulation
25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion
Comments
October 2023 - Routinely available in line with national guidance